Allergan Aesthetics, an AbbVie companyy announces the FDA approval of JUVÉDERM® VOLBELLA® XC for improvement of infraorbital hollows in adults over the age of 21.2 According to clinical trial data, 90% of subjects

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In